NCT05876091 is a NA clinical trial of Vaping in Tobacco-Related Carcinoma, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT05876091?

NCT05876091 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT05876091?

Interventions in NCT05876091: Vaping, Biospecimen Collection, Questionnaire Administration.

What condition does NCT05876091 study?

NCT05876091 studies Tobacco-Related Carcinoma.

Is NCT05876091 still recruiting?

NCT05876091 is currently terminated. Last updated 22 December 2025.

Are results published for NCT05876091?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-12-22 · How we verify

NCT05876091

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography

Terminated NA Results posted Last updated 22 December 2025

What this trial tests

NA trial testing Vaping in Tobacco-Related Carcinoma in 21 participants. Terminated before completion.

Timeline

30 August 2023

Primary endpoint
8 October 2024

29 October 2024

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	21
Start date	30 August 2023
Primary completion	8 October 2024
Estimated completion	29 October 2024
Sites	1 location across United States

Drugs / interventions tested

Vaping
Biospecimen Collection — full drug profile →
Questionnaire Administration

Conditions studied

Tobacco-Related Carcinoma — all drugs for Tobacco-Related Carcinoma →

Sponsor

Roswell Park Cancer Institute

Who can join

Adults 21 to 55, any sex, with Tobacco-Related Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Puff Topography: Puff Count Primary · Single Session, Approximately 2 hours in duration

Measure of vaping topography counting total number of puffs.

Group	Value	95% CI
Session 1: Own Brand Puff Count Ad Lib	13.9	± 2.3
Session 1: Own Brand Puff Count Directed	6.4	± 0.8
Sessions 2-5: Cowboy Vaping Liquid Puff Count Ad Lib	13.2	± 2.2
Sessions 2-5: Cowboy Vaping Liquid Puff Count Directed	5.8	± 0.8
Sessions 2-5: RY4 Double Vaping Liquid Puff Count Ad Lib	15.4	± 3.1
Sessions 2-5: RY4 Double Vaping Liquid Puff Count Directed	5.9	± 0.9
Sessions 2-5: Unflavored Vaping Liquid Puff Count Ad Lib	13.2	± 2.2
Sessions 2-5: Unflavored Vaping Liquid Puff Count Directed	5.8	± 0.9
Sessions 2-5: Red Oak Vaping Liquid Puff Count Ad Lib	13.0	± 2.2
Sessions 2-5: Red Oak Vaping Liquid Puff Count Directed	6.3	± 1.2
Session 6-7: Synthetic Nicotine Liquid Puff Count Ad Lib	14.3	± 2.4
Session 6-7: Synthetic Nicotine Liquid Puff Count Directed	7.1	± 0.9

Puff Topography: Puff Duration (in Seconds) Primary · Single Session, Approximately 2 hours in duration

Measure of vaping topography counting duration of puffs in seconds.

Group	Value	95% CI
Session 1: Own Brand Puff Duration Ad Lib	2.2	± 0.3
Session 1: Own Brand Puff Duration Directed	3.5	± 0.3
Sessions 2-5: Cowboy Vaping Liquid Puff Duration Ad Lib	2.3	± 0.3
Sessions 2-5: Cowboy Vaping Liquid Puff Count Directed	3.1	± 0.3
Sessions 2-5: RY4 Double Vaping Liquid Puff Count Ad Lib	2.5	± 0.4
Sessions 2-5: RY4 Double Vaping Liquid Puff Count Directed	3.0	± 0.3
Sessions 2-5: Unflavored Vaping Liquid Puff Count Ad Lib	2.3	± 0.3
Sessions 2-5: Unflavored Vaping Liquid Puff Count Directed	3.2	± 0.3
Sessions 2-5: Red Oak Vaping Liquid Puff Count Ad Lib	2.1	± 0.2
Sessions 2-5: Red Oak Vaping Liquid Puff Count Directed	2.9	± 0.3
Session 6-7: Synthetic Nicotine Liquid Puff Duration Ad Lib	2.4	± 0.4
Session 6-7: Synthetic Nicotine Liquid Puff Duration Directed	3.0	± 0.3

Puff Topography: Inter Puff Interval (IPI) Primary · Single Session, Approximately 2 hours in duration

Measure of vaping topography counting the interval between puffs in seconds.

Group	Value	95% CI
Session 1: Own Brand Inter Puff Interval Ad Lib	82.2	± 14.0
Session 1: Own Brand Inter Puff Interval Directed	55.2	± 6.1
Sessions 2-5: Cowboy Vaping Inter Puff Interval Ad Lib	61.4	± 10.7
Sessions 2-5: Cowboy Vaping Liquid Inter Puff Interval Directed	58.0	± 4.2
Sessions 2-5: RY4 Double Vaping Liquid Inter Puff Interval Ad Lib	71.6	± 10.3
Sessions 2-5: RY4 Double Vaping Liquid Inter Puff Interval Directed	54.2	± 3.6
Sessions 2-5: Unflavored Vaping Liquid Inter Puff Interval Ad Lib	71.6	± 8.7
Sessions 2-5: Unflavored Vaping Liquid Inter Puff Interval Directed	56.7	± 4.0
Sessions 2-5: Red Oak Vaping Liquid Inter Puff Interval Ad Lib	55.1	± 8.1
Sessions 2-5: Red Oak Vaping Liquid Inter Puff Interval Directed	60.6	± 5.4
Session 6-7: Synthetic Nicotine Liquid Inter Puff Interval Ad Lib	84.6	± 12.0
Session 6-7: Synthetic Nicotine Liquid Inter Puff Interval Directed	59.3	± 4.1

Puff Topography: Puff Volume Primary · Single Session, Approximately 2 hours in duration

Measure of vaping topography measuring the volume per puff in ml.

Group	Value	95% CI
Session 1: Own Brand Puff Volume Ad Lib	63.5	± 13.2
Session 1: Own Brand Puff Volume Directed	102.2	± 16.1
Sessions 2-5: Cowboy Vaping Liquid Puff Volume Ad Lib	66.2	± 11.4
Sessions 2-5: Cowboy Vaping Liquid Puff Volume Directed	81.4	± 14.7
Sessions 2-5: RY4 Double Vaping Liquid Puff Volume Ad Lib	83.6	± 17.2
Sessions 2-5: RY4 Double Vaping Liquid Puff Volume Directed	103.1	± 18.6
Sessions 2-5: Unflavored Vaping Liquid Puff Volume Ad Lib	63.9	± 8.1
Sessions 2-5: Unflavored Vaping Liquid Puff Volume Directed	88.3	± 13.5
Sessions 2-5: Red Oak Vaping Liquid Puff Volume Ad Lib	57.5	± 6.5
Sessions 2-5: Red Oak Vaping Liquid Puff Volume Directed	74.9	± 10.61
Session 6-7: Synthetic Nicotine Liquid Puff Volume Ad Lib	86.7	± 14.9
Session 6-7: Synthetic Nicotine Liquid Puff Volume Directed	96.3	± 13.5

Puff Topography: Flow Rate Primary · Single Session, Approximately 2 hours in duration

Measure of vaping topography measuring the rate of flow per puff in milliliters per second.

Group	Value	95% CI
Session 1: Own Brand Flow Rate Ad Lib	28.4	± 3.4
Session 1: Own Brand Flow Rate Directed	28.7	± 3.3
Sessions 2-5: Cowboy Vaping Liquid Flow Rate Ad Lib	28.2	± 2.3
Sessions 2-5: Cowboy Vaping Liquid Flow Rate Directed	25.5	± 2.7
Sessions 2-5: RY4 Double Vaping Liquid Flow Rate Ad Lib	29.3	± 2.4
Sessions 2-5: RY4 Double Vaping Liquid Flow Rate Directed	24.8	± 2.6
Sessions 2-5: Unflavored Vaping Liquid Flow Rate Ad Lib	27.8	± 2.9
Sessions 2-5: Unflavored Vaping Liquid Flow Rate Directed	25.2	± 2.8
Sessions 2-5: Red Oak Vaping Liquid Flow Rate Ad Lib	27.8	± 2.4
Sessions 2-5: Red Oak Vaping Liquid Flow Rate Directed	24.2	± 1.9
Session 6-7: Synthetic Nicotine Liquid Flow Rate Ad Lib	33.7	± 2.1
Session 6-7: Synthetic Nicotine Liquid Flow Rate Directed	31.4	± 2.1

Subjective Questionnaires of Product Evaluation Secondary · Single Session, Approximately 2 hours in duration

Will be assessed by Duke Sensory Scale

Draw (0 "less draw" - 100 "more draw)

Group	Value	95% CI
Session 1: Own Brand Ad Lib	72.3	± 7.3
Session 1: Own Brand Directed	77.0	± 5.7
Sessions 2-5: Cowboy Vaping Liquid Ad Lib	69.7	± 4.4
Sessions 2-5: Cowboy Vaping Liquid Directed	64.1	± 5.6
Sessions 2-5: RY4 Double Vaping Liquid Ad Lib	61.1	± 6.5
Sessions 2-5: RY4 Double Vaping Liquid Directed	71.6	± 4.5
Sessions 2-5: Red Oak Vaping Liquid Ad Lib	72.9	± 4.7
Sessions 2-5: Red Oak Vaping Liquid Directed	75.5	± 4.2
Sessions 2-5: Unflavored Vaping Liquid Ad Lib	68.8	± 5.0
Sessions 2-5: Unflavored Vaping Liquid Directed	72.5	± 4.7
Sessions 6-7: Synthetic Nicotine Ad Lib	71.9	± 5.0
Sessions 6-7: Synthetic Nicotine Directed	74.2	± 5.3

Pleasantness (-100 "less pleasant" - +100 "more pleasant")

Group	Value	95% CI
Session 1: Own Brand Ad Lib	45.2	± 12.0
Session 1: Own Brand Directed	33.2	± 15.9
Sessions 2-5: Cowboy Vaping Liquid Ad Lib	-3.2	± 15.3
Sessions 2-5: Cowboy Vaping Liquid Directed	-32.6	± 15.5
Sessions 2-5: RY4 Double Vaping Liquid Ad Lib	3.9	± 13.1
Sessions 2-5: RY4 Double Vaping Liquid Directed	-2.5	± 13.3
Sessions 2-5: Red Oak Vaping Liquid Ad Lib	16.4	± 15.2
Sessions 2-5: Red Oak Vaping Liquid Directed	37.7	± 15.7
Sessions 2-5: Unflavored Vaping Liquid Ad Lib	-2.0	± 14.8
Sessions 2-5: Unflavored Vaping Liquid Directed	22.4	± 16.2
Sessions 6-7: Synthetic Nicotine Ad Lib	26.2	± 11.6
Sessions 6-7: Synthetic Nicotine Directed	21.2	± 12.9

Tingling Sensation (0 "less tingling sensation" - 100 "more tingling sensation")

Group	Value	95% CI
Session 1: Own Brand Ad Lib	50.2	± 11.4
Session 1: Own Brand Directed	34.8	± 8.6
Sessions 2-5: Cowboy Vaping Liquid Ad Lib	34.2	± 6.6
Sessions 2-5: Cowboy Vaping Liquid Directed	44.4	± 4.9
Sessions 2-5: RY4 Double Vaping Liquid Ad Lib	38.9	± 6.5
Sessions 2-5: RY4 Double Vaping Liquid Directed	44.7	± 7.8
Sessions 2-5: Red Oak Vaping Liquid Ad Lib	25.4	± 5.3
Sessions 2-5: Red Oak Vaping Liquid Directed	45.1	± 6.3
Sessions 2-5: Unflavored Vaping Liquid Ad Lib	36.2	± 5.6
Sessions 2-5: Unflavored Vaping Liquid Directed	33.4	± 5.1
Sessions 6-7: Synthetic Nicotine Ad Lib	27.8	± 5.3
Sessions 6-7: Synthetic Nicotine Directed	29.8	± 5.7

Product Evaluation Score: Satisfaction (1 "not at all" - 7 "extremely")

Group	Value	95% CI
Session 1: Own Brand Ad Lib	4.8	± 0.4
Session 1: Own Brand Directed	4.2	± 0.4
Sessions 2-5: Cowboy Vaping Liquid Ad Lib	2.8	± 0.3
Sessions 2-5: Cowboy Vaping Liquid Directed	2.6	± 0.4
Sessions 2-5: RY4 Double Vaping Liquid Ad Lib	2.7	± 0.3
Sessions 2-5: RY4 Double Vaping Liquid Directed	3.0	± 0.4
Sessions 2-5: Red Oak Vaping Liquid Ad Lib	3.1	± 0.4
Sessions 2-5: Red Oak Vaping Liquid Directed	3.4	± 0.4
Sessions 2-5: Unflavored Vaping Liquid Ad Lib	3.1	± 0.4
Sessions 2-5: Unflavored Vaping Liquid Directed	2.9	± 0.4
Sessions 6-7: Synthetic Nicotine Ad Lib	3.4	± 0.3
Sessions 6-7: Synthetic Nicotine Directed	3.4	± 0.3

Product Evaluaton Sore: Relief (1 "not at all" - 7 "extremely")

Group	Value	95% CI
Session 1: Own Brand Ad Lib	5.3	± 0.4
Session 1: Own Brand Directed	4.7	± 0.6
Sessions 2-5: Cowboy Vaping Liquid Ad Lib	3.9	± 0.3
Sessions 2-5: Cowboy Vaping Liquid Directed	4.4	± 0.3
Sessions 2-5: RY4 Double Vaping Liquid Ad Lib	4.0	± 0.3
Sessions 2-5: RY4 Double Vaping Liquid Directed	4.2	± 0.3
Sessions 2-5: Red Oak Vaping Liquid Ad Lib	4.3	± 0.3
Sessions 2-5: Red Oak Vaping Liquid Directed	4.1	± 0.3
Sessions 2-5: Unflavored Vaping Liquid Ad Lib	4.5	± 0.3
Sessions 2-5: Unflavored Vaping Liquid Directed	4.5	± 0.3
Sessions 6-7: Synthetic Nicotine Ad Lib	4.8	± 0.3
Sessions 6-7: Synthetic Nicotine Directed	4.7	± 0.4

Sponsor's own description

This clinical trial tests the effect of tobacco flavor and liquid composition on the way a person puffs on a vape (topography). In general, tobacco products are designed with sensory factors in mind, such as flavor, to increase the appeal. Flavors and the composition of nicotine, either made in a lab (synthetic) or from tobacco, may create positive sensory effects, such as look, feel and taste, and influence smoking behavior and willingness to try different types of cigarettes. Understanding how nicotine vaping products are used is important in assessing individual and population level health risks. Vape flavors and synthetic nicotine may be related to harmful effects on health from vaping and may impact the appeal, risk beliefs and vaping topography.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vaping

Trials testing the same drug.

NCT06260683 — A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior · NA · recruiting

Other recruiting trials for Tobacco-Related Carcinoma

Currently open trials in the same condition.

NCT07049757 — Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities · NA · recruiting
NCT07346092 — Studying the Health Perceptions and Social Behaviors of Graduate Students at the Ohio State University for the Developme · NA · recruiting
NCT06315881 — Informing Oral Nicotine Pouch Regulations to Promote Public Health · Phase 2 · recruiting
NCT06249984 — Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff · NA · recruiting
NCT06583148 — A Smoke-Free Home Intervention in Tribal Communities · NA · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05876091 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 22 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05876091.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing